Showing 5311-5320 of 21466 results for "".
- Rapalogix Health Launches Re-Q Pro-Longevity Serum with Focus on Cellular Skin Aginghttps://reachmd.com/news/rapalogix-health-launches-re-q-pro-longevity-serum-with-focus-on-cellular-skin-aging/2487003/Rapalogix Health has introduced its new Re-Q Pro-Longevity Face Serum during a virtual launch event on Thursday, May 7, featuring co-Founder and board-certified dermatologist Doris Day, MD, and co-Founder and CEO Rahul Mehta. The webinar focused on the science behind the product and the company’s
- Aspirin and Elevated Lp(a) in Primary Preventionhttps://reachmd.com/news/aspirin-and-elevated-lpa-in-primary-prevention/2486999/Key Takeaways Overall pooled data did not suggest lower MACE with aspirin in the broader elevated-Lp(a) primary-prevention population. Lower pooled estimates were observed for myocardial infarction and cardiovascular mortality, while coronary artery di
- GA Depot Trial Reports Lower Relapse Activity vs Placebohttps://reachmd.com/news/ga-depot-trial-reports-lower-relapse-activity-vs-placebo/2486997/Key Takeaways GA Depot was associated with reduced relapse activity and less contrast-enhancing MRI activity than placebo over 52 weeks. The phase 3 randomized placebo-controlled trial studied intramuscular GA Depot 40 mg every 4 weeks in adults with r
- Upadacitinib in Rheumatoid Arthritis: Dose-Specific Pooled Findingshttps://reachmd.com/news/upadacitinib-in-rheumatoid-arthritis-dose-specific-pooled-findings/2486991/Key Takeaways Both 15 mg and 30 mg once daily were associated with improved ACR20 response at 12 weeks versus control. No significant efficacy difference was observed between the two doses in the direct pooled comparison. Adverse events rose w
- Persistent Vomiting After Pediatric ED Dischargehttps://reachmd.com/news/persistent-vomiting-after-pediatric-ed-discharge/2486989/Key Takeaways Persistent vomiting after discharge was reported in 8.6% of children and was concentrated in younger patients. The pediatric ongoing vomiting score incorporated younger age, 24 to 48 hours of symptoms, and 10 or more recent vomiting episo
- Phase 2a Trial Of JNJ-67484703 In Atopic Dermatitishttps://reachmd.com/news/phase-2a-trial-of-jnj-67484703-in-atopic-dermatitis/2486983/Key Takeaways Week 12 EASI-75 was higher with JNJ-67484703 than placebo, but the between-group difference was not statistically significant. EASI improvement, EASI-50, and SCORAD also moved in a numerically favorable direction with JNJ-67484703. <
- Analysis: Black Children Show Lower Dermatology Specialty Care Use Despite Higher Disease Frequencyhttps://reachmd.com/news/black-children-show-lower-dermatology-use-despite-higher-disease-frequency/2486986/Black children had higher electronic health record (EHR)–derived frequencies of atopic dermatitis (AD), acne, and hidradenitis suppurativa compared with White children across 8 US children’s hospitals. Investigators for the multicenter cross-sectional study
- Review Examines Dermatologic Effects of Rapid Weight Losshttps://reachmd.com/news/review-examines-dermatologic-effects-of-rapid-weight-loss/2486984/Rapid weight loss associated with bariatric surgery, glucagon-like peptide-1 receptor agonists (GLP-1 RA), and intensive lifestyle interventions may contribute to dermatologic and structural changes that extend beyond reduced body size, according to a narrative rev
- Direct Transfer To Angiography Suite In Severe Acute Strokehttps://reachmd.com/news/direct-transfer-to-angiography-suite-in-severe-acute-stroke/2486969/Key Takeaways In the intention-to-treat analysis, direct transfer was not associated with better 90-day functional independence than the conventional pathway. Symptomatic intracranial haemorrhage was reported more often with direct transfer, while 90-d
- Final RATIONALE-315 Analysis Supports Perioperative Tislelizumabhttps://reachmd.com/news/final-rationale-315-analysis-supports-perioperative-tislelizumab/2486962/Key Takeaways Perioperative tislelizumab remained associated with longer overall survival, and event-free survival also remained improved at final follow-up. Survival patterns were generally similar across reported subgroups, while exploratory tumor mu